Mark Velleca Net Worth
The estimated Net Worth of Mark A. Velleca is at least $2.55 Million dollars as of 17 January 2019. Mr. Velleca owns over 9,000 units of G1 Therapeutics stock worth over $634,480 and over the last 2 years he sold GTHX stock worth over $0. In addition, he makes $1,914,650 as President, Chief Executive Officer, and Director at G1 Therapeutics.
Mr. Velleca GTHX stock SEC Form 4 insider trading
Mark has made over 13 trades of the G1 Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 9,000 units of GTHX stock worth $3,510 on 17 January 2019.
The largest trade he’s ever made was exercising 15,000 units of G1 Therapeutics stock on 11 October 2018 worth over $22,500. On average, Mark trades about 6,600 units every 26 days since 2017. As of 17 January 2019 he still owns at least 28,000 units of G1 Therapeutics stock.
You can see the complete history of Mr. Velleca stock trades at the bottom of the page.
Mark Velleca biography
Mark A. Velleca M.D., Ph.D. is the President, Chief Executive Officer, Director of G1 Therapeutics Inc. Dr. Velleca has served as our Chief Executive Officer, President and a member of our Board of Directors since May 2014. Prior to joining us, Dr. Velleca was a co-founder and served as Senior Vice President of CGI Pharmaceuticals, Inc., or CGI, a biopharmaceutical company, from 1999 to 2010, where he managed the company from its inception through clinical trials of multiple drug candidates. After CGI was acquired by Gilead Sciences, Inc., or Gilead, a biotechnology company, in 2010, Dr. Velleca served as a Senior Advisor to Gilead from 2010 to April 2012, where he worked to help build its oncology pipeline. Dr. Velleca has served on the board of directors of BioMarker Strategies, a private oncology diagnostics company, from 2010 to 2012, and on the scientific advisory boards of BioRelix Inc., a biopharmaceutical company, from 2007 to 2012 and Intellikine, Inc., a biopharmaceutical company, from 2007 to 2010. Dr. Velleca most recently served as Executive Vice President at The Leukemia & Lymphoma Society from April 2012 to April 2014. Dr. Velleca also served as an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine. Dr. Velleca received his B.S. from Yale University, and his M.D. and Ph.D. from Washington University in St. Louis. Velleca’s perspective and experience as our Chief Executive Officer and President, as well as his depth of experience in the biotechnology industry, provide him with the qualifications and skills to serve on our Board of Directors.
What is the salary of Mark Velleca?
As the President, Chief Executive Officer, and Director of G1 Therapeutics, the total compensation of Mark Velleca at G1 Therapeutics is $1,914,650. There are 3 executives at G1 Therapeutics getting paid more, with John Demaree having the highest compensation of $7,466,410.
How old is Mark Velleca?
Mark Velleca is 55, he’s been the President, Chief Executive Officer, and Director of G1 Therapeutics since 2014. There are 9 older and 5 younger executives at G1 Therapeutics. The oldest executive at G1 Therapeutics, Inc. is Fredric Eshelman, 70, who is the Independent Director.
Insider trading at G1 Therapeutics
Over the last 2 years, insiders at G1 Therapeutics have traded over $51,509,269 worth of G1 Therapeutics stock and bought 1,482,753 units worth $23,467,604 . The most active insider traders include Capital Management, Llcra C…, Fredric N Eshelman, and Glenn P Muir. On average, G1 Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $994,813. The most recent stock trade was executed by Jennifer K. Moses on 18 July 2019, trading 2,000 units of GTHX stock currently worth $7,440.
What does G1 Therapeutics do?
G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
What does G1 Therapeutics’s logo look like?
Complete history of Mr. Velleca stock trades at G1 Therapeutics
G1 Therapeutics executives and stock owners
G1 Therapeutics executives and other stock owners filed with the SEC include:
- John Demaree, Chief Commercial Officer
- James Hanson, General Counsel
- Terry Murdock, Chief Operating Officer
- Mark Velleca, President, Chief Executive Officer, Director
- Garry Nicholson, Independent Chairman of the Board
- Barclay Phillips, Chief Financial Officer and Senior Vice President – Corporate Development
- Rajesh Malik, Chief Medical Officer, Senior Vice President – Research and Development
- Cynthia Schwalm, Independent Director
- Willie Deese, Independent Director
- Seth Rudnick, Independent Director
- Glenn Muir, Independent Director
- Fredric Eshelman, Independent Director
- Andrew Witty, Independent Director
- Jeff Macdonald, Head of Investor Relations/Public Relations
- Jennifer Moses, Vice President – Finance and Accounting
- Jay Strum, Chief Scientific Officer
- Clay Hatteras Venture Advis…,
- Capital Management, Llcra C…,
- Christy L Shaffer, Director
- Ventures, Inc. Med Immune, 10% owner
- Ventures, Llc Eshelman, 10% owner
- Clay Hatteras Venture Advis…,
- Mark Avagliano, Chief Business Officer